ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: BMS Oncology Names New VP, Marketing; Hortobagyi Wins Freyer Medal; Prerez Honored

October 24, 1997

New ACR Mammography Guidelines Suggest Annual Screening For Women Age 40-50

November 12, 1982

Study Finds No Benefit for Frequent CA125 Testing in Recurrent Ovarian Cancer

June 5, 2009

HCRA Response On DRGs and Clinical Research Threat Called A “Stone Wall,” Legislative Remedy Sought

July 27, 1984

Survival After Liver Transplant Called Excellent In Study

November 28, 2003

Cancer Deaths Level Off For First Time, Klausner Tells House Appropriators.

February 18, 2000